Delving into the Latest Updates on Anhui Provincial Institute of Translational Medicine with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Digestive System Disorders

Monoclonal antibody

Biosimilar

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Biosimilar	1
Monoclonal antibody	1

Top 5 Target	Count

VEGF-A(Vascular endothelial growth factor A)	1

Midbrain astrocyte-derived neurotrophic factor (MANF) is a secreted protein induced by endoplasmic reticulum stress. Previous studies have indicated that intravenous administration of 1 mg/kg/day recombinant human MANF protein with His tag (His-MANF) for 3 days can ameliorate acute ulcerative colitis in mice. However, long-term intravenous therapy has many disadvantages. In this paper, His-MANF protein was successfully encapsulated into alginate and hyaluronic acid hybrid hydrogel microcapsules in one step using the gas shear method and then coated by Eudragit S100 to construct an oral colon-targeted delivery system (MSH@E). The MSH@E microcapsules exhibited controlled and sustained release behavior and colon-targeting properties. Both fluorescent imaging and immunohistochemistry staining results showed that His-MANF protein could accumulate in the colitis colon for a longer residence time after oral delivery. In vivo studies demonstrated that oral administration of MSH@E microcapsules could alleviate DSS-induced colitis in mice without systemic toxicity. Importantly, even if the oral His-MANF dose was half of the intravenous His-MANF dose, oral delivery was still much more effective than intravenous injection, suggesting the development of the oral colon-targeted delivery system (MSH@E) has great significance and makes a breakthrough from intravenous to oral administration for His-MANF treatment of ulcerative colitis (UC).

23 Apr 2025·Nano Letters

High Efficiency Production of Functional Small Extracellular Vesicles through Cellular Self-Motivation

Article

Author: Zhang, Shuxin ; Chen, Xu-Lin ; Zhao, Xinyu ; Yan, Tianhao ; Wang, Xianwen ; Li, Xiaoru ; Chen, Ye ; Qiao, Zihan ; Wang, Chen ; Wu, Shangquan ; Chen, Qiubo ; Wu, Wenjie ; Zhang, Qingchuan

In stem cell therapies, small extracellular vesicles (sEVs) are extremely limited in application due to their limited production. Here, we propose a new concept of "cellular self-stimulation" and develop a cost-effective method for the preparation of sEVs, which enables the conversion of cellular traction to self-generated stimulation through piezoionic hydrogels and enhances the ability of cells to secrete sEVs by more than an order of magnitude. The traction of the adherent cells leads to deformation of the piezoionic substrate, which in turn translates into a millivolt-level electrical signal acting on the cell itself, stimulating the cell to produce more sEVs. These sEVs remain biologically intact and have shown excellent efficacy in in vitro and in vivo assays, confirming the superior therapeutic potential of high concentrations of sEVs. This provides a strong impetus for the development and dissemination of stem cell therapies.

09 Apr 2025·ACS Applied Materials & Interfaces

Fe₃O₄@Bi₂S₃ Nanoparticles Mediated MRI-Guided Precision Radiosensitization for Orthotopic Glioblastoma via External Magnetism

Article

Author: Jiang, Yechun ; Xu, Lingling ; Fu, Wanyue ; Yu, Yongqiang ; Qian, Haisheng ; Song, Xiaowei ; Xiao, Liang ; Zheng, Wang ; Chen, Benjin

Radioresistance in tumors and the excess damage in normal tissues during radiotherapy (RT) restrict the clinical application of glioblastoma RT. Image-guided radiosensitization is hopefully adopted to achieve precision RT. Nevertheless, the therapeutic effect of radiosensitizers in glioblastoma is unsatisfactory due to limitations of the blood-brain barrier and poor tumor targeting. Herein, Fe₃O₄@Bi₂S₃ nanoparticles coated with a glioblastoma cell membrane (denoted as FBM) have been designed to sensitize RT. FBM accumulates precisely within the tumors via external magnetism and homologous adhesion capability. Afterward, FBM releases high-Z atoms (Bismuth) in ionizing radiation and tumor micro acidic environments that interact with ionizing radiation to generate high densities of secondary radiation, which leads to enhanced radiation dose deposits. Simultaneously, FBM generates reactive oxygen species, accumulates lipid peroxidation and Fe²⁺, depletes glutathione, and downregulates glutathione peroxidase 4 to activate ferroptosis. Notably, the tumor growth inhibition rate of FBM-mediated RT via external magnetism increases to 75.49% in the orthotopic glioblastoma model. Besides, FBM with magnetic resonance imaging performance shows the potential application in tumor diagnosis and therapy surveillance, thereby reducing damage to adjacent normal tissues and realizing MRI-guided precision RT. Hence, the novel multifunctional nanoplatform offers the potential for image-guided radiosensitization induced by activating ferroptosis, thus presenting an efficient radiotherapeutic approach for glioblastoma.

100 Deals associated with Anhui Provincial Institute of Translational Medicine

Login to view more data

100 Translational Medicine associated with Anhui Provincial Institute of Translational Medicine

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data